Mohamed Attya, Amira Taha, Sherif Ali Gamal Eldin, Riham Assem Elessawy, Ahmed Abdallah Mohalhal
{"title":"Vitreous level of tumor necrosis factor alpha in patients with macular edema secondary to retinal vein occlusion.","authors":"Mohamed Attya, Amira Taha, Sherif Ali Gamal Eldin, Riham Assem Elessawy, Ahmed Abdallah Mohalhal","doi":"10.1177/11206721251332791","DOIUrl":null,"url":null,"abstract":"<p><p>PurposeRetinal vein occlusion (RVO) induces ischemia that triggers the release of inflammatory cytokines, including tumor necrosis factor alpha (TNF- α). We aimed at measuring TNF- α level in vitreous samples of treatment naïve RVO patients.Material and Methodsthis is a case control study. The study was conducted on 45 eyes (20 eyes with treatment naïve RVO associated with macular edema & 25 eyes of patients undergoing cataract surgery as control). Vitreous samples were collected using 25 gauge needle connected to 1 milliliters (ml) syringe and the level of TNF- α was assessed using Enzyme-linked Immunosorbent Assay (ELISA) Kits<b>.</b>ResultsThe mean age of RVO cases was 51.50 ± 12.86 years while controls was 55.76 ± 6.88 years (P value =0.192). Vitreous level of TNF-α was statistically significant higher in RVO patients [4.92 ± 0.74 picograms (pg)/ ml] than control [3.54 ± 0.60 pg/ml]; p value < 0.001. Vitreous TNF-α level in ischemic and non-ischemic RVO subgroups was 4.94 ± 0.69 pg/ml and 4.89 ± 0.89 pg/ml respectively that wasn't statistically significant (p value = 0.885) and its level in branch and central RVO subgroups was 5.02 ± 0.79 pg/ml and 4.84 ± 0.73pg/ml respectively not statistically significant (p value = 0.592).ConclusionsTNF-α level is increased in vitreous of RVO associated macular edema patients, thus, it may be involved in its pathogenesis and Anti-TNF-α might be used as treatment targets in the future.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"1710-1716"},"PeriodicalIF":1.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721251332791","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
PurposeRetinal vein occlusion (RVO) induces ischemia that triggers the release of inflammatory cytokines, including tumor necrosis factor alpha (TNF- α). We aimed at measuring TNF- α level in vitreous samples of treatment naïve RVO patients.Material and Methodsthis is a case control study. The study was conducted on 45 eyes (20 eyes with treatment naïve RVO associated with macular edema & 25 eyes of patients undergoing cataract surgery as control). Vitreous samples were collected using 25 gauge needle connected to 1 milliliters (ml) syringe and the level of TNF- α was assessed using Enzyme-linked Immunosorbent Assay (ELISA) Kits.ResultsThe mean age of RVO cases was 51.50 ± 12.86 years while controls was 55.76 ± 6.88 years (P value =0.192). Vitreous level of TNF-α was statistically significant higher in RVO patients [4.92 ± 0.74 picograms (pg)/ ml] than control [3.54 ± 0.60 pg/ml]; p value < 0.001. Vitreous TNF-α level in ischemic and non-ischemic RVO subgroups was 4.94 ± 0.69 pg/ml and 4.89 ± 0.89 pg/ml respectively that wasn't statistically significant (p value = 0.885) and its level in branch and central RVO subgroups was 5.02 ± 0.79 pg/ml and 4.84 ± 0.73pg/ml respectively not statistically significant (p value = 0.592).ConclusionsTNF-α level is increased in vitreous of RVO associated macular edema patients, thus, it may be involved in its pathogenesis and Anti-TNF-α might be used as treatment targets in the future.
期刊介绍:
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.